RPT-193 is a small molecule commercialized by RAPT Therapeutics, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of RPT-193’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for RPT-193 is expected to reach an annual total of $542 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RPT-193 Overview

RPT-193 (FLX-193) is under development for the treatment of allergic disorders including atopic dermatitis (eczema), asthma, chronic urticaria (skin rash), allergic conjunctivitis, chronic rhinosinusitis and eosinophilic esophagitis. The drug candidate is administered orally. It acts by targeting chemokine receptor type 4 (CCR4).

RAPT Therapeutics Overview

RAPT Therapeutics operates as an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compounds such as FLX475 which blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate cancer. The company has advanced into the clinic with a dual-inhibitor drug that targets FLT3 and CDK4 and 6 for the treatment of cancer. RAPT Therapeutics is headquartered in South San Francisco, California, the US

The company reported revenues of (US Dollars) US$3.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 24.4% over FY2020. The operating loss of the company was US$69.2 million in FY2021, compared to an operating loss of US$53.2 million in FY2020. The net loss of the company was US$69.2 million in FY2021, compared to a net loss of US$52.9 million in FY2020.

For a complete picture of RPT-193’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.